BMC complementary medicine and therapies · 2025
Endometriosis-like lesions induced by phthalates: new phytotherapic applications to complement traditional cares: a PNRR 2023 project.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tassinari Roberta, D'Archivio Massimo, Varì Rosaria, Scazzocchio Beatrice, Lori Gabriele, Bellenghi Maria, Silenzi Annalisa, Tammaro Alessia, Marcoccia Daniele, Tassinari Valentina, Smeriglio Antonella, Trombetta Domenico, Maiorana Antonio, Leone Maria Clara, Maranghi Francesca
Аннотация
BACKGROUND: Endometriosis (E) is an oestrogen-dependent, multifactorial, inflammatory disease causing pelvic pain and infertility. Several concerns have been raised about the role of food contaminants, in particular Bis(2-ethylhexyl) phthalate (DEHP), potentially involved in the onset and propagation of E. Conventional therapies- which have considerable side effects - focus on reducing levels of oestrogens and counteracting inflammation. The potential preventive/protective role of plant extracts (PEs) on phthalate (PH) -induced E is studied by a stepwise approach.
METHODS: (i) raw material identification, extraction and phytochemical characterization; (ii) in vitro tests to evaluate pharmacokinetics and organotropism; (iii) in vitro screening on 2 human endometrial cell lines and in vivo toxicokinetic to select the PEs/BCs in comparison with non-steroidal anti-inflammatory drugs; (iv) in vivo juvenile toxicity study to test the PE/BC activity on DEHP induced E-like lesions and (v) ex vivo and in vitro studies on human E primary cells obtained by patients with E to be subjected to scheduled surgical procedures and human non-cancerous cells, to investigate the DEHP and metabolite concentration and PE/BC effects, respectively.
DISCUSSION: The project aims to provide data and tools to develop a new strategy based on herbal medicine- especially polyphenolic compounds for their pleiotropic activities - to mitigate the E symptoms and to prevent and/or to protect population - including susceptible sub-groups - from the onset of E. The outcomes of the project will support the Italian National Health System in the development of complementary alternative/preventive strategies for E and to set clinical studies on humans also considering the potential role of environmental contaminants in E pathogenesis.
CLINICAL TRIAL NUMBER: Not applicable.
METHODS: (i) raw material identification, extraction and phytochemical characterization; (ii) in vitro tests to evaluate pharmacokinetics and organotropism; (iii) in vitro screening on 2 human endometrial cell lines and in vivo toxicokinetic to select the PEs/BCs in comparison with non-steroidal anti-inflammatory drugs; (iv) in vivo juvenile toxicity study to test the PE/BC activity on DEHP induced E-like lesions and (v) ex vivo and in vitro studies on human E primary cells obtained by patients with E to be subjected to scheduled surgical procedures and human non-cancerous cells, to investigate the DEHP and metabolite concentration and PE/BC effects, respectively.
DISCUSSION: The project aims to provide data and tools to develop a new strategy based on herbal medicine- especially polyphenolic compounds for their pleiotropic activities - to mitigate the E symptoms and to prevent and/or to protect population - including susceptible sub-groups - from the onset of E. The outcomes of the project will support the Italian National Health System in the development of complementary alternative/preventive strategies for E and to set clinical studies on humans also considering the potential role of environmental contaminants in E pathogenesis.
CLINICAL TRIAL NUMBER: Not applicable.